Immunovant director sells 2,502 shares in plan trade

Immunovant, Inc. director Robert Graham Susman reported an open-market sale of 2,502 shares of common stock at a weighted average price of $27.17 per share.

Rhea-AI Filing Summary

Immunovant, Inc. director Robert Graham Susman reported an open-market sale of 2,502 shares of common stock at a weighted average price of $27.17 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 30, 2025.

Following this sale, he directly holds 36,394 shares of Immunovant common stock, so the filing reflects a partial reduction rather than an exit from his position.

Insider Trade Summary 10b5-1

Net Seller: 2,502 shares

Net Sell 1 txn

Insider Susman Robert Graham

Role Director

Sold 2,502 shs ($68K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,502	$27.17	$68K

Holdings After Transaction: Common Stock — 36,394 shares (Direct)

Footnotes (2)

1. F1. The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 2,502 shares Weighted average sale price: $27.17 per share Post-transaction holdings: 36,394 shares +1 more

4 metrics

Shares sold 2,502 shares Open-market sale of common stock

Weighted average sale price $27.17 per share Common stock sale on May 1, 2026

Post-transaction holdings 36,394 shares Shares directly held after sale

Price range of trades $26.84–$27.49 per share Range of prices across multiple sale executions

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunovant (IMVT) director Robert Graham Susman do in this Form 4 filing?

Robert Graham Susman reported an open-market sale of 2,502 Immunovant shares at a weighted average price of $27.17. This was a planned trade under a Rule 10b5-1 plan, rather than a spontaneous market decision.

How many Immunovant (IMVT) shares did the director sell and at what price?

He sold 2,502 shares of Immunovant common stock at a weighted average price of $27.17 per share. Individual trades occurred between $26.84 and $27.49, according to the disclosed price range in the footnote.

How many Immunovant (IMVT) shares does the director hold after this transaction?

After the reported sale, Robert Graham Susman directly holds 36,394 shares of Immunovant common stock. This indicates he retained a substantial remaining position following the relatively small open-market sale reported in the filing.

Was the Immunovant (IMVT) insider sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on December 30, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions.

What does the price range in the Immunovant (IMVT) Form 4 footnote mean?

The footnote explains the reported price is a weighted average of multiple trades executed between $26.84 and $27.49 per share. The director offers to provide exact share counts at each price level to the issuer, shareholders, or the SEC upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susman Robert Graham

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S		2,502(1)	D	$27.17(2)	36,394	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, Attorney-in-Fact for Robert Susman	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)